Trials / Terminated
TerminatedNCT03648437
Paracetamol And Ibuprofen/Indomethacin in Closing Patent Ductus Arteriosus
Paracetamol And Ibuprofen/Indomethacin in Closing Patent Ductus Arteriosus of Preterm Infants - Randomised, Placebo-controlled Multicentre Trial
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- University of Oulu · Academic / Other
- Sex
- All
- Age
- 4 Months
- Healthy volunteers
- Not accepted
Summary
The purpose of this pilot trial is to study efficacy and safety of simultaneous intravenous (iv) ibuprofen/indomethacin and paracetamol medications in the closure of patent ductus arteriosus (PDA) in preterm infants. It is randomized, placebo-controlled, double-blind, phase 1, multicenter, clinical trial.
Detailed description
Premature infants (born before 37 weeks gestational age) with patent ductus arteriosus (PDA) are the focus of the study since no trials on the additive efficacy of these two medications on the contraction of ductus arteriosus are available. Preterm infants who are diagnosed to have a hemodynamically significant PDA and who, according to the decision of the attending clinician, need ibuprofen/indomethacin therapy, are eligible to this trial. If the parents deny the consent, the patient will be treated according to the standard PDA treatment: three days' iv ibuprofen Pedea® 5mg/ml solution infusion (Oulu, Helsinki, Tartu) dosing: 10mg/kg + 5mg/kg + 5mg/kg (q24h); or three days' iv indomethacin (Turku) 0.2mg/kg + 0.1mg/kg + 0.1mg/kg (q24h). In case of any contraindications for ibuprofen/indomethacin, the treatment would be surgical ligation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paracetamol 10Mg/mL | Experimental drug |
| DRUG | 0.45% Sodium Chloride | Placebo comparator |
| DRUG | Ibuprofen | Standard therapy |
| DRUG | Indomethacin | Standard therapy |
Timeline
- Start date
- 2018-09-03
- Primary completion
- 2024-10-04
- Completion
- 2024-10-04
- First posted
- 2018-08-27
- Last updated
- 2024-10-18
Locations
4 sites across 1 country: Finland
Source: ClinicalTrials.gov record NCT03648437. Inclusion in this directory is not an endorsement.